medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2015, Number 1

<< Back Next >>

Rev Invest Clin 2015; 67 (1)

Morbidity and Mortality Following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy at a Tertiary Care Center: Initial Experience

Clemente-Gutiérrez U, Garza-Gangemi A, Trejo-Gómez G, Medina-Franco H

Language: English
References: 28
Page: 39-45
PDF size: 204.68 Kb.


ABSTRACT

Background: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy increases progression-free and overall survival in patients with peritoneal carcinomatosis of appendicular or colorectal origin. The morbidity associated with this procedure is significant (30-52%). This modality is also routinely used in other peritoneal diseases with improvement of outcome. The aim of this study was to analyze the morbidity and mortality associated with this procedure. Material & Methods: Thirteen patients had cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a period from May 2011 to March 2013 and were followed up prospectively. Demographic, pathologic, and surgical variables were recorded. The Clavien-Dindo classification was used to assess surgical complications. The main outcome variable was 30-day morbidity and mortality. Descriptive statics were used. Results: The mean patient age was 52.4 ± 11.1 years. The most common diagnosis was epithelial ovarian cancer (46.2%). Most patients had an adequate preoperative functional status (77% with ECOG 0). Mean hospital stay was 13.5 ± 11.2 days and 2.7 ± 4.2 days in the intensive care unit. Major morbidity (Clavien-Dindo III or IV) observed in this series was 23%, with 0% mortality. Conclusion: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is a feasible option with acceptable morbidity and mortality for selected patients with peritoneal carcinomatosis in Mexico.


REFERENCES

  1. Sugarbaker PH. Overview of Peritoneal Carcinomatosis. Cancerologia. 2008;3:119-24.

  2. Sugarbaker PH. Peritonectomy Procedures. Ann Surg. 1995; 221:29-42.

  3. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;1:358-63.

  4. Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: Multi-institutional experience. J Clin Oncol. 2009;27:6237-42.

  5. Sugarbaker PH. Carcinomatosis--Is Cure an Option? J Clin Oncol. 2003;21:762-4.

  6. Roviello F, Pinto E, Corso G, et al. Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer. J Surg Oncol. 2010;102:663-70.

  7. Rao G, Crispens M, Rothenberg ML. Intraperitoneal chemotherapy for ovarian cancer: Overview and perspective. J Clin Oncol. 2007;25:2867-72.

  8. Golse N, Bakrin N, Passot G, et al. Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: Postoperative and long-term results. J Surg Oncol. 2012;106:197-203.

  9. Di Giorgio A, Biacchi D, Sibio S, et al. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer. 2008;113:315-25.

  10. Reichman TW, Cracchiolo B, Sama J. Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma. J Surg Oncol. 2005;90:51-6.

  11. Verwaal Vic, van Ruth S, de Bree Eelco. et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737-43.

  12. López-Basave HN, Morales-Vásquez F, Ruiz Molina JM, et al. Morbidity and mortality of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: national cancer institute, Mexico city, Mexico. ISRN oncology. 2011;2011:526384.

  13. Mohamed F, Moran BJ. Morbidity and mortality with cytoreductive surgery and intraperitoneal chemotherapy. Cancer J. 2009; 15:196-9.

  14. Kusamura S, Dominique E, Baratti D, et al. Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2008;98:247-52.

  15. Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21:4560-7.

  16. Younan R, Kusamura S, Baratti D, et al. Morbidity, toxicity, and mortality classification systems in the local regional treatment of peritoneal surface malignancy. J Surg Oncol. 2008;98:253-7.

  17. González-Moreno S, Ortega-Pérez G, González-Bayón L. Indications and patient selection for cytoreductive surgery and perioperative intraperitoneal chemotherapy. J Surg Oncol. 2009;100:287-92.

  18. Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205-13.

  19. Markman M. Intraperitoneal chemotherapy of ovarian cancer: A review, with a focus on practical aspects of treatment. J Clin Oncol. 2006;24:988-94.

  20. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet. 2009;374:1371-82.

  21. Chua TC, Yan TD, Saxena A, et al. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? Ann Surg. 2009;249:900-7.

  22. Kusamura S, Baratti D, Virzi S, Bonomi S. Learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies: analysis of two centres. J Surg Oncol. 2013;107:312-19.

  23. Elias D, Goere D, Blot F, et al. Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients. Ann Surg Oncol. 2007;14:1818-24.

  24. Van Leeuwen BL, Graf W, Pahlman L, et al. Swedish experience with peritonectomy and HIPEC. HIPEC in peritoneal carcinomatosis. Ann Surg Oncol. 2008;15:745-53.

  25. Rufian S, Muñoz-Casares F, Briceño J, et al. Radical surgeryperitonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. Ann Surg Oncol. 2006;94:316-24.

  26. Gusani NJ, Cho SW, Colovos C, et al. Aggressive surgical management of peritoneal carcinomatosis with low mortality in a highvolume tertiary cancer center. Ann Surg Oncol. 2008;15:754-63.

  27. Glehen O, Osinsky D, Cotte E, et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: Morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol. 2003;10:863-9.

  28. Sugarbaker PH, Alderman R, Edwards G, et al. Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol. 2006;13:635-44.




2020     |     www.medigraphic.com